ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its holdings in shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) by 153.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 202,368 shares of the company's stock after acquiring an additional 122,641 shares during the period. Charles Schwab Investment Management Inc. owned 0.60% of ArriVent BioPharma worth $4,756,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of AVBP. Novo Holdings A S increased its position in ArriVent BioPharma by 0.4% in the 3rd quarter. Novo Holdings A S now owns 1,505,315 shares of the company's stock valued at $35,375,000 after acquiring an additional 5,315 shares during the period. SG Americas Securities LLC acquired a new position in shares of ArriVent BioPharma in the third quarter valued at approximately $280,000. Rhumbline Advisers raised its stake in shares of ArriVent BioPharma by 30.1% during the second quarter. Rhumbline Advisers now owns 12,707 shares of the company's stock worth $236,000 after purchasing an additional 2,942 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of ArriVent BioPharma by 31.4% during the second quarter. Bank of New York Mellon Corp now owns 29,847 shares of the company's stock worth $554,000 after purchasing an additional 7,140 shares during the period. Finally, AlphaCentric Advisors LLC grew its position in ArriVent BioPharma by 3.6% in the 2nd quarter. AlphaCentric Advisors LLC now owns 86,000 shares of the company's stock valued at $1,595,000 after buying an additional 3,000 shares during the last quarter. 9.48% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have commented on AVBP. HC Wainwright restated a "buy" rating and set a $36.00 price objective on shares of ArriVent BioPharma in a research report on Friday, November 15th. Citigroup raised their price objective on shares of ArriVent BioPharma from $30.00 to $36.00 and gave the company a "buy" rating in a research report on Wednesday, September 11th. Oppenheimer reiterated an "outperform" rating and set a $39.00 target price (up previously from $35.00) on shares of ArriVent BioPharma in a research report on Tuesday, September 10th. Finally, The Goldman Sachs Group increased their target price on ArriVent BioPharma from $28.00 to $38.00 and gave the stock a "buy" rating in a research note on Tuesday, September 10th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, ArriVent BioPharma currently has an average rating of "Buy" and a consensus price target of $36.80.

ArriVent BioPharma Trading Up 3.2 %

AVBP traded up $0.84 on Friday, hitting $26.72. 148,278 shares of the company were exchanged, compared to its average volume of 171,669. ArriVent BioPharma, Inc. has a fifty-two week low of $14.35 and a fifty-two week high of $36.37. The business's fifty day moving average is $29.48 and its 200 day moving average is $24.43.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.